Curated News
By: NewsRamp Editorial Staff
February 25, 2026

VolitionRx Advances Cancer, Sepsis Detection with New Biomarkers and Licensing Talks

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • VolitionRx's new cancer detection method targets a $23 billion market, offering investors and partners early access to lucrative diagnostics through licensing agreements.
  • VolitionRx uses Capture-Seq technology and Nu.Q assays for cancer detection, with clinical progress in lung cancer reimbursement and sepsis detection through government programs.
  • VolitionRx's blood tests enable earlier cancer and sepsis detection, potentially saving lives and improving patient outcomes through accessible, cost-effective diagnostics.
  • VolitionRx's veterinary assay detects feline lymphoma with 100% specificity, demonstrating cross-species applications of their epigenetic technology beyond human medicine.

Impact - Why it Matters

This news matters because VolitionRx's advancements in epigenetic blood tests could revolutionize early disease detection, potentially saving lives and reducing healthcare costs. For patients, earlier diagnosis of cancers like lung cancer or conditions like sepsis through non-invasive tests means better treatment outcomes and improved quality of life. In veterinary care, the breakthrough in feline lymphoma detection offers hope for pet owners, enhancing animal welfare. The company's progress toward commercialization and licensing agreements with global diagnostic leaders signals growing industry validation, which could accelerate the availability of these tests worldwide. With an estimated $23 billion market opportunity, Volition's innovations have significant economic implications, potentially disrupting traditional diagnostic methods and contributing to public health advancements.

Summary

VolitionRx Ltd., a multi-national epigenetics company trading on the NYSE American under the symbol VNRX, has provided a comprehensive update on its clinical and commercial advancements across key platforms. The company highlighted significant progress in cancer detection, including the submission of a manuscript for peer review that showcases a new method called Capture-Seq and novel biomarkers, estimating an annualized total addressable market opportunity of approximately $23 billion. Commercialization efforts for the Nu.Q Cancer assay in lung cancer are advancing, with reimbursement submission in France on track and routine clinical use anticipated by Q4 2026. Additionally, Volition confirmed inclusion of its Nu.Q NETs assay in the $7.3 million government-backed DETECSEPS program in France for early sepsis detection and presented new clinical utility data for its assay in Hidradenitis Suppurativa, which is CE-marked and available across Europe.

In veterinary medicine, Volition reported breakthrough results demonstrating 100% specificity in detecting feline lymphoma using its Nu.Q Vet Feline assay, with publication of the study expected to unlock a $5 million contractual milestone payment. The company is also engaged in ongoing licensing discussions with approximately 10 global diagnostic leaders and anticipates announcing additional licensing agreements during 2026. For further details, the full press release can be accessed via BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN, which focuses on the latest developments in biotechnology and life sciences. Volition's research and development activities are centered in Belgium, with additional facilities in the U.S. and London, emphasizing its commitment to saving lives through earlier disease detection and monitoring.

Volition's innovations span human and veterinary applications, leveraging epigenetics to develop simple, cost-effective blood tests for diseases like cancer and sepsis. The company's progress in clinical validation and commercialization underscores its potential to transform diagnostic markets, with key milestones including regulatory approvals and strategic partnerships. Media enquiries can be directed to Louise Batchelor at Volition, and more information is available on the company's website. This update reflects Volition's dedication to improving patient and animal outcomes through advanced epigenetic technologies, positioning it as a leader in the rapidly evolving field of precision diagnostics.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VolitionRx Advances Cancer, Sepsis Detection with New Biomarkers and Licensing Talks

blockchain registration record for this content.